017180.KS
MYUNGMOON Pharm co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,150.00
−1.12%Year over year
Reported trailing growth
- Revenue
- +4.8%
- EBITDA
- -85.2%
- EBIT
- -81.7%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.7%
- EBITDA
- -1.6%
- EBIT
- +2.0%
- Net income
- -37.8%
- EPS
- -37.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026